Carotid Body Tumor - 25 Studies Found

Terminated : Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
:
  • Pheochromocytoma
  • Paraganglioma

: 2009-05-29
Completed : Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
:
  • Paraganglioma
  • Pheochromocytoma

: 2009-02-12
: Drug: Sunitinib 50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
Recruiting : First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
: 2011-06-09
:
  • Drug: Sunitinib sunitinib 37.5
Active, not recruiting : Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
:
  • Paragangliomas
  • Pheochromocytomas

: 2014-06-04
: Other: PET-CT
Completed : Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
:
  • Pheochromocytoma
  • Paraganglioma

: 2007-04-09
: Drug: Ultratrace Iobenguane (MIBG) I 131 Phase I: Dose escalation protocol Phase II: Treatment schedule
Active, not recruiting : A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
:
  • Pheochromocytoma
  • Paraganglioma

: 2009-04-01
: Radiation: Ultratrace® Iobenguane I131 Each subject will be administered 3 mCi to 6 mCi Ultratrace&
Available : Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
:
  • Pheochromocytoma
  • Paraganglioma

: 2016-11-08
: Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who
Active, not recruiting : Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
:
  • Pheochromocytoma
  • Paraganglioma

: 2013-10-19
: Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o
Withdrawn : Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
:
  • Phaeochromocytoma
  • Paraganglioma

: 2013-09-10
:
  • Drug: Vandetanib 100 mg, 200 m
Not yet recruiting : Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
:
  • Malignant Adrenal Gland Pheochromocytoma
  • Malignant Paraganglioma : 2016-12-28
    :
    • Other: Laboratory Biomarker Analysis

Next >>>